Royalty Pharma plc
Climate Impact & Sustainability Data (2021, 2022, 2023)
Reporting Period: 2021
Environmental Metrics
Total Carbon Emissions:315,679 tCO2e (Scope 3, Category 15)
Scope 1 Emissions:113 tCO2e
Scope 2 Emissions:113 tCO2e
Scope 3 Emissions:315,679 tCO2e (Category 15)
ESG Focus Areas
- Governance
- Employee well-being
- Environmental sustainability
- Responsible investment
Environmental Achievements
- Achieved ENERGY STAR certification and WELL designation for New York headquarters
- Encouraging green building certification at headquarters
- Reimbursing Citi Bike memberships for employees to encourage carbon-free commutes
- Installing water fountains to support reusable water bottles
Social Achievements
- Launched employee learning and development program with 100% of initial participants finding it useful
- Offered 16 weeks of parental leave for the primary caregiver and 4 weeks for the secondary caregiver
- Maintained a voluntary and involuntary turnover rate of 3.4% each in 2021
- 100% of employees completed annual compliance training in 2021
- Donated $5.3 million to support COVID-19 research between 2020 and 2021
- Donated over $700,000 to six organizations in 2021
Governance Achievements
- Completed a materiality assessment in 2022, consulting investors, employees, senior management, and the board of directors
- Adopted a robust Cybersecurity and Personal Data Breach Policy
- Implemented a strong compensation recovery (“Clawback”) policy for the Manager and executive officers
- Adopted proxy voting policies and procedures in accordance with Rule 206(4)-6 of the Investment Advisers Act
- Implemented a Whistleblower Hotline hosted by an independent third party
Climate Goals & Targets
Short-term Goals:
- 100% of employees to complete the employee learning and development program
Environmental Challenges
- Risk of scams and security breaches
- ESG-related risks associated with portfolio companies
Mitigation Strategies
- Security measures in place to ensure data security and protection
- Robust due diligence process for new investments, including ESG and reputational risk assessment
- Engagement with subject-matter experts and special advisors as needed
Supply Chain Management
Responsible Procurement
- Royalty Pharma Supplier Code of Conduct
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI, SASB
Reporting Period: 2022
Environmental Metrics
Total Carbon Emissions:19,610 tCO2e/year (Scope 3 Category 15)
Scope 1 Emissions:–
Scope 2 Emissions:–
Scope 3 Emissions:19,610 tCO2e/year
ESG Focus Areas
- Corporate Governance
- ESG Governance
- Responsible Investment
- Access to Health and Medicine
- Diversity, Equity and Inclusion
- Human Capital Management
Environmental Achievements
- Reduced operational footprint through energy-efficient office lighting and water filtration system.
- Published Greenhouse Gas emissions (GHG) data for 2021 and 2022 with limited assurance from Ernst & Young LLP.
Social Achievements
- 11.9% headcount growth in 2022 with 5.6% total turnover.
- Donated and pledged approximately $29 million in 2022 to non-profits focused on health equity and underserved communities.
- Launched a matching charitable donation program in 2022.
- Expanded opportunities for employee professional development.
- Improved the comprehensive benefits offered to employees.
Governance Achievements
- Conducted first materiality assessment.
- Improved transparency through publication of ESG fact sheet and 2021 GRI and SASB Summary.
- 90% of Board is independent.
Climate Goals & Targets
Long-term Goals:
- Achieve carbon neutrality (timeline not specified).
Environmental Challenges
- Measuring and reducing Scope 3 emissions.
- Addressing systemic inequities in healthcare access.
Mitigation Strategies
- Expanding Scope 3 emissions measurements and creating a framework to reduce impact.
- Established partnerships with organizations focused on health equity research (e.g., Mount Sinai, Leukemia & Lymphoma Society).
Supply Chain Management
Responsible Procurement
- Supplier Code of Conduct (addresses ethical and labor concerns).
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI, SASB
Third-party Assurance: Ernst & Young LLP (limited assurance for GHG emissions)
UN Sustainable Development Goals
- SDG 3 (Good Health and Well-being)
Funding innovation in biopharmaceutical industry and treating diseases.
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:32,002 tCO2e/year
Scope 1 Emissions:N/A
Scope 2 Emissions:N/A
Scope 3 Emissions:32,002 tCO2e/year
ESG Focus Areas
- Responsible Investment
- Access to Health and Medicine
- Diversity, Equity and Inclusion
- Human Capital Management
- Corporate Governance
Environmental Achievements
- Provided online training on sustainability and recycling efforts and procedures.
- New York City office is Energy Star certified and WELL designated.
Social Achievements
- Formed a Diversity, Equity and Inclusion (DEI) Task Force.
- Conducted employee engagement survey.
- Offered two internship programs.
- Donated $7.5 million to non-profit organizations.
- Low employee turnover (6.2% average total turnover past three years).
Governance Achievements
- Implemented Responsible Investment Policy.
- Expanded Board of Director Oversight on Sustainability and Responsible Business-Related Topics.
- Published inaugural Corporate Responsibility Report.
- 100% of employees certified compliance with Code of Business Conduct and Ethics.
- 100% of employees completed mandatory ethics training.
Climate Goals & Targets
Environmental Challenges
- Sustainability and responsible business risks and opportunities extend beyond our immediate operations as they are also manifested in our partners’ businesses.
- Scope 3 emissions related to portfolio investments are the most material emissions category.
Mitigation Strategies
- Published Responsible Investment Policy to further formalize robust due diligence process.
- Incorporated human rights considerations into investment practices.
- Calculated Scope 3 Category 15 GHG emissions by disaggregating portfolio and applying emission intensity factors.
- Expanded Scope 3 emissions measurements.
Supply Chain Management
Responsible Procurement
- Supplier Code of Conduct
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI, SASB
Third-party Assurance: Apex Companies, LLC
UN Sustainable Development Goals
- SDG 3
Social Bond Framework contributes to SDG 3.